Literature DB >> 1751893

Human chorionic gonadotrophin and sport.

A T Kicman1, R V Brooks, D A Cowan.   

Abstract

Human chorionic gonadotrophin (hCG) is a glycoprotein hormone which is produced in large amounts during pregnancy and also by certain types of tumour. The biological action of hCG is identical to that of luteinizing hormone, although the former has a much longer plasma half-life. Some male athletes use pharmaceutical preparations of hCG to stimulate testosterone production before competition and/or to prevent testicular shutdown and atrophy during and after prolonged courses of androgen administration. Testosterone administration can be detected by measuring the ratio of concentrations of testosterone to epitestosterone (T/E). An athlete is often considered to have failed a drug test if the urinary T/E ratio is greater than 6. In contrast, hCG administration stimulates the endogenous production of both testosterone and epitestosterone without increasing the urinary T/E ratio above normal values. Although the administration of hCG was banned by the International Olympic Committee (IOC) in 1987, no definitive test for hCG has been approved by the IOC. Currently, the only way of measuring small concentrations of hCG is by immunoassay, and this does not have a discriminating power as great as gas-liquid chromatography with mass-spectrometry which is necessary to satisfy IOC requirements. Extraction procedures and chromatographic steps could be introduced before using a selected immunoassay for hCG to meet these requirements.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1751893      PMCID: PMC1478834          DOI: 10.1136/bjsm.25.2.73

Source DB:  PubMed          Journal:  Br J Sports Med        ISSN: 0306-3674            Impact factor:   13.800


  38 in total

1.  THE SECOND INTERNATIONAL STANDARD FOR CHORIONIC GONADOTROPHIN.

Authors:  D R BANGHAM; B GRAB
Journal:  Bull World Health Organ       Date:  1964       Impact factor: 9.408

Review 2.  Androgen abuse by athletes.

Authors:  J D Wilson
Journal:  Endocr Rev       Date:  1988-05       Impact factor: 19.871

Review 3.  What are we measuring in gonadotropin assays?

Authors:  S L Jeffcoate
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1988

4.  Evidence for the rapid internalization and recycling of lutropin receptors in rat testis Leydig cells.

Authors:  A D Habberfield; C J Dix; B A Cooke
Journal:  Biochem J       Date:  1986-01-15       Impact factor: 3.857

Review 5.  Molecular biology of steroid hormone synthesis.

Authors:  W L Miller
Journal:  Endocr Rev       Date:  1988-08       Impact factor: 19.871

6.  Criteria to indicate testosterone administration.

Authors:  A T Kicman; R V Brooks; S C Collyer; D A Cowan; M N Nanjee; G J Southan; M J Wheeler
Journal:  Br J Sports Med       Date:  1990-12       Impact factor: 13.800

7.  Testicular responsiveness to human chorionic gonadotrophin during transient hypogonadotrophic hypogonadism induced by androgenic/anabolic steroids in power athletes.

Authors:  H Martikainen; M Alén; P Rahkila; R Vihko
Journal:  J Steroid Biochem       Date:  1986-07       Impact factor: 4.292

8.  Studies of the heterogeneity of human pituitary LH by fast protein liquid chromatography.

Authors:  A Stockell Hartree; J B Lester; R C Shownkeen
Journal:  J Endocrinol       Date:  1985-06       Impact factor: 4.286

9.  Circulating antibodies to mouse monoclonal immunoglobulins in normal subjects--incidence, species specificity, and effects on a two-site assay for creatine kinase-MB isoenzyme.

Authors:  R J Thompson; A P Jackson; N Langlois
Journal:  Clin Chem       Date:  1986-03       Impact factor: 8.327

10.  False positive immunometric assays caused by anti-immunoglobulin antibodies: a case report.

Authors:  J L Bock; J Furgiuele; B Wenz
Journal:  Clin Chim Acta       Date:  1985-04-30       Impact factor: 3.786

View more
  1 in total

Review 1.  Gonadotropins in doping: pharmacological basis and detection of illicit use.

Authors:  U-H Stenman; K Hotakainen; H Alfthan
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.